跳转至内容
Merck
CN

D122

多潘立酮

≥98% (HPLC), Dopamine D2 receptor antagonist, powder

别名:

4-(5-Chloro-2-oxo-1-benzimidazolinyl)-1-[3-(2-oxobenzimidazolinyl)propyl]piperidine

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C22H24ClN5O2
化学文摘社编号:
57808-66-9
分子量:
425.91
NACRES:
NA.77
PubChem Substance ID:
24277911
UNSPSC Code:
12352200
EC Number:
260-968-7
MDL number:
MFCD00069256
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

多潘立酮, powder, ≥98% (HPLC)

InChI key

FGXWKSZFVQUSTL-UHFFFAOYSA-N

InChI

1S/C22H24ClN5O2/c23-15-6-7-20-18(14-15)25-22(30)28(20)16-8-12-26(13-9-16)10-3-11-27-19-5-2-1-4-17(19)24-21(27)29/h1-2,4-7,14,16H,3,8-13H2,(H,24,29)(H,25,30)

SMILES string

Clc1ccc2N(C3CCN(CCCN4C(=O)Nc5ccccc45)CC3)C(=O)Nc2c1

assay

≥98% (HPLC)

form

powder

color

white

solubility

DMSO: >10 mg/mL, 0.1 M HCl: soluble, 0.1 M NaOH: slightly soluble, H2O: insoluble

originator

Johnson & Johnson

Quality Level

100

Gene Information

human ... DRD1(1812), DRD2(1813), DRD3(1814), DRD4(1815), DRD5(1816), KCNH2(3757)
rat ... Drd1a(24316), Drd2(24318), Drd3(29238), Htr3a(79246)

正在寻找类似产品? 访问 产品对比指南

相关类别

Biochem/physiol Actions

Peripheral dopamine receptor antagonist that does not cross the blood-brain barrier; anti-emetic.

Features and Benefits

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Health hazard
GHS08

signalword

Warning

hcodes

H361fd

Hazard Classifications

Repr. 2

存储类别

11 - Combustible Solids

wgk

WGK 3

ppe

Eyeshields, Gloves, type P3 (EN 143) respirator cartridges

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000523132
0000523132
0000523134
0000523134
0000477538

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity.
P M Laduron et al.
Biochemical pharmacology, 28(14), 2161-2165 (1979-07-15)
Luc M Hondeghem
Journal of cardiovascular pharmacology, 61(3), 218-225 (2012-11-29)
Domperidone (antinausea/vomiting agent) was recently shown by several groups to increase sudden cardiac death (SCD). Drug-induced disturbances of cardiac repolarization may be a major mechanism. Experiments were executed in isolated female rabbit hearts perfused for 150 minutes with domperidone 30
D S Pritchard et al.
British journal of clinical pharmacology, 59(6), 725-729 (2005-06-14)
To determine whether there is robust evidence of efficacy for domperidone in reducing the symptoms of gastro-oesophageal reflux (GOR) and gastro-oesophageal reflux disease (GORD) in children. Systematic review of randomized controlled trials (RCTs). A search was made of the Cochrane
M C Champion et al.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 135(5), 457-461 (1986-09-01)
Domperidone is a dopamine antagonist that has recently been released in Canada. Unlike metoclopramide hydrochloride, the other available dopamine antagonist, it does not readily enter the central nervous system. Domperidone acts as both an antiemetic and an upper gastrointestinal tract
C K Brown et al.
Clinical pharmacy, 9(5), 357-365 (1990-05-01)
The pathophysiology, diagnosis, and treatment of diabetic gastroparesis are reviewed, and the mechanisms of action, pharmacokinetics, clinical efficacy, adverse effects, and dosage of metoclopramide, domperidone, and cisapride are described. Diabetic gastroparesis is a state of delayed gastric emptying that reportedly
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持